CSL Behring LLC	Stimate [®] (desmopressin acetate)	Package Insert Revised: June 2013 Page 1
CSL Behring		
	Stimate [®])
	(desmopressin ace	
	Nasal Spray, 1.5 m	
R _x only		
DESCRIPTION		
Stimate [®] (desmopressi arginine vasopressin (A	ADH), an antidiuretic hormo	ogue of the natural pituitary hormone one affecting renal water conservations in acetate in an aqueous solution at a p
of approximately 5. Stir	nate [®] Nasal Spray's compres	sion pump delivers 0.1 mL (150 mcg)
· · ·	hemically defined as follows:	
Mol. Wt. 1183.34 Empirica	al formula: $C_{46}H_{64}N_{14}O_{12}S_2 \bullet C_2H_4O_2 $	3H ₂ O
O SCH ₂ CH ₂ C-Tyr-Phe-GIn-As 1 2 3 4 5	n-Cys-Pro-D-Arg-Gly-NH ₂ +CH ₃ COOF 6 7 8 9	I+3H₂0
1-(3-mercaptopropionic	acid)-8-D-arginine vasopressin	monoacetate (salt) trihydrate.
Stimate [®] Nasal Spray i	s provided as an aqueous soluti	on for intranasal use.
Each mL contains:		
Active ingredient:		
Desmopressin aceta	ate	1.5 mg
Inactive ingredients:		
Sodium chloride Buffer:		7.5 mg
Citric acid mon	obydrate	1.7 mg
	phate dihydrate	3 mg
Preservative:	r	0
Benzalkonium	chloride	0.1 mg
Purified water		To 1 mL
CLINICAL PHARMA		
sumate Nasal Spray	contains as active substance, d	esmopressin acetate, which is a synthe
stimate [®] Nasal Spray	a normone arginine vasopress	in. One spray or 0.1 mL (150 mcg)
Sumate masar spray s	orution has an antionuretic activ	vity of about 600 International Units.
Decmonressin acatate ho	as been shown to be more note	nt than arginine vasopressin in increasi
-	-	hemophilia and von Willebrand's disea
GRDC\Cabinets\RA Labeling\St	imate\USA\Package Insert, Blank [77875	59] \Rev. 11/2012

VERSION 17.0

Reference ID: 3322618

CBE_Delete References

CSL Behring LLC	Stimate [®]	Package Insert
	(desmopressin acetate)	Revised: June 2013
		Page 2

Dose-response studies were performed in healthy persons using doses of 150 to 450 mcg, administered as one to three sprays. The response to **Stimate**[®] **Nasal Spray** is dose-related, with maximal plasma levels of 150 to 250 percent of initial concentrations achieved for both Factor VIII and von Willebrand factor. The increase is rapid and evident within 30 minutes, reaching a maximum at about 1.5 hours.

38

The percentage increase of Factor VIII and von Willebrand factor levels in patients with mild 39 hemophilia A and von Willebrand's disease was not notably different from that observed in 40 normal healthy individuals when treated with 300 mcg of Stimate[®] Nasal Spray. In patients 41 with von Willebrand's disease, levels of Factor VIII coagulant activity and von Willebrand factor 42 antigen remained greater than 30 U/dL for 8 hours after a 300 mcg dose of Stimate[®] Nasal 43 Spray. After 300 mcg of Stimate[®] Nasal Spray, the percentage increase of Factor VIII and von 44 Willebrand factor levels in patients with mild hemophilia A and von Willebrand's disease was 45 less than observed after 0.3 mcg/kg of intravenous desmopressin acetate. 46

47

Plasminogen activator activity increases rapidly after intravenous desmopressin acetate infusion,
 but there has been no clinically significant fibrinolysis in patients treated with desmopressin
 acetate.

51

The effect of repeated intravenous desmopressin acetate administration when doses were given every 12 to 24 hours has generally shown a diminution of the Factor VIII activity increase noted after a single dose. It is possible to reproduce the initial response in some patients after an interval of one week, but other patients may require as long as 6 weeks.

56

The half-life of **Stimate[®] Nasal Spray** was between 3.3 and 3.5 hours, over the range of intranasal doses, 150 to 450 mcg. Plasma concentrations of **Stimate[®] Nasal Spray** were maximal approximately 40 to 45 minutes after dosing.

60

The bioavailability of **Stimate**[®] **Nasal Spray** when administered by the intranasal route as a 1.5 mg/mL solution is between 3.3 and 4.1 percent.

63

The change in structure of arginine vasopressin to desmopressin acetate has resulted in a decreased vasopressor action and decreased actions on visceral smooth muscle relative to the enhanced antidiuretic activity, so that clinically effective antidiuretic doses are usually below threshold levels for effects on vascular or visceral smooth muscle.

68

69 INDICATIONS AND USAGE

Before the initial therapeutic administration of **Stimate[®] Nasal Spray**, the physician should establish that the patient shows an appropriate change in the coagulation profile following a test dose of intranasal administration of **Stimate[®] Nasal Spray**.

- 73
- 74 Desmopressin acetate is also available as a solution for injection (DDAVP[®] Injection) when the
- ⁷⁵ intranasal route may be compromised. These situations include nasal congestion and blockage,
- nasal discharge, atrophy of nasal mucosa, and severe atrophic rhinitis. Intranasal delivery may
- also be inappropriate where there is an impaired level of consciousness.

CSL Behring LLC	Stimate [®]	Package Insert
	(desmopressin acetate)	Revised: June 2013
		Page 3

78

79 Hemophilia A

80 **Stimate[®] Nasal Spray** is indicated for patients with hemophilia A with Factor VIII coagulant 81 activity levels greater than 5%.

82

Beside Be

86

In the outpatient setting during two clinical trials where patients recorded bleeding episodes, **Stimate[®] Nasal Spray** provided effective hemostasis 100% of the time in 2 of the 5 patients. For those patients not responding in 100% of bleeding occasions, 45% (14 of 31) of bleeding episodes were effectively controlled with **Stimate[®] Nasal Spray**.

91

Desmopressin acetate is not indicated for the treatment of hemophilia A with Factor VIII coagulant activity levels equal to or less than 5%, or for the treatment of hemophilia B, or in patients who have Factor VIII antibodies.

95

96 von Willebrand's Disease (Type I)

Stimate[®] Nasal Spray is indicated for patients with mild to moderate classic von Willebrand's
 disease (Type I) with Factor VIII levels greater than 5%.

99

Desmopressin acetate will also stop bleeding in mild to moderate von Willebrand's disease
 patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses,
 intramuscular hematomas, mucosal bleeding or menorrhagia.

103

In the outpatient setting during two clinical trials where patients recorded bleeding episodes, **Stimate[®] Nasal Spray** provided effective hemostasis 100% of the time in 75% of the patients (n=16). For those patients not responding in 100% of bleeding occasions, 78% (64 of 82) of bleeding episodes were effectively controlled with **Stimate[®] Nasal Spray**.

108

Patients may respond in a variable fashion depending on the type of molecular defect they have.
 Bleeding time and Factor VIII coagulant activity, ristocetin cofactor activity, and von Willebrand
 factor antigen should be checked after initial administration of Stimate[®] Nasal Spray to ensure
 that adequate levels have been achieved.

113

Stimate[®] Nasal Spray is not indicated for the treatment of severe classic von Willebrand's disease (Type I) and when there is evidence of an abnormal molecular form of Factor VIII antigen. See *WARNINGS*.

117

118 **CONTRAINDICATIONS**

- 119 None.
- 120
- 121

CSL Behring LLC	Stimate [®]	Package Insert
0	(desmopressin acetate)	Revised: June 2013
		Page 4

122 WARNINGS

123 For intranasal use only.

124

Very rare cases of hyponatremia have been reported from world-wide postmarketing experience in patients treated with Stimate (desmopressin acetate). Stimate is a potent antidiuretic which, when administered, may lead to water intoxication and/or hyponatremia. Unless properly diagnosed and treated hyponatremia can be fatal. Therefore, fluid restriction is recommended and should be discussed with the patient and/or guardian. Careful medical supervision is required.

131

When Stimate Nasal Spray is administered, in particular in pediatric and geriatric patients, fluid 132 intake should be adjusted downward in order to decrease the potential occurrence of water 133 intoxication and hyponatremia (See PRECAUTIONS, Pediatric Use and Geriatric Use.) All 134 patients receiving Stimate therapy should be observed for the following signs or symptoms 135 associated with hyponatremia: headache, nausea/vomiting, decreased serum sodium, weight 136 gain, restlessness, fatigue, lethargy, disorientation, depressed reflexes, loss of appetite, 137 irritability, muscle weakness, muscle spasms or cramps and abnormal mental status such as 138 139 hallucinations, decreased consciousness and confusion. Severe symptoms may include one or a combination of the following: seizure, coma and/or respiratory arrest. Particular attention should 140 be paid to the possibility of the rare occurrence of an extreme decrease in plasma osmolality that 141 may result in seizures that could lead to coma. 142

143

144 Stimate should be used with caution in patients with habitual or psychogenic polydipsia, who 145 may be more likely to drink excessive amounts of fluids, putting them at greater risk of 146 hyponatremia.

147

150

Stimate[®] Nasal Spray should not be used to treat patients with Type IIB von Willebrand's
 disease since platelet aggregation may be induced.

151 **PRECAUTIONS**

152 General

Desmopressin acetate has infrequently produced changes in blood pressure causing either a slight elevation in blood pressure or a transient fall in blood pressure and a compensatory increase in heart rate. The drug should be used with caution in patients with coronary artery insufficiency and/or hypertensive cardiovascular disease.

157

Stimate[®] Nasal Spray should be used with caution in patients with conditions associated with fluid and electrolyte imbalance, such as cystic fibrosis, heart failure and renal disorders because these patients are prone to hyponatremia.

161

162 There have been rare reports of thrombotic events (thrombosis, acute cerebrovascular 163 thrombosis, acute myocardial infarction) following desmopressin acetate injection in patients 164 predisposed to thrombus formation. No causality has been determined; however, the drug should 165 be used with coution in these patients

- be used with caution in these patients.
- 166

CSL Behring LLC	Stimate [®]	Package Insert
2	(desmopressin acetate)	Revised: June 2013
		Page 5

- 167 Severe allergic reactions have been reported rarely. Fatal anaphylaxis has been reported in one 168 patient who received intravenous DDAVP[®] (desmopressin acetate). It is not known whether 169 antibodies to desmopressin acetate are produced after repeated administration.
- 170

Since Stimate[®] Nasal Spray is used intranasally, changes in the nasal mucosa such as scarring,
edema, or other disease may cause erratic, unreliable absorption in which case Stimate[®] Nasal
Spray should be discontinued until the nasal problems resolve. For such situations, DDAVP[®]
Injection should be considered.

175

176 Information for Patients

Patients should be informed that the bottle accurately delivers 25 sprays of 150 mcg each. Any solution remaining after 25 sprays should be discarded since the amount delivered thereafter may be substantially less than 150 mcg of drug. No attempt should be made to transfer remaining solution to another bottle. Patients should be instructed to read accompanying directions on use of the spray pump carefully before use.

182

Patients should also be advised that if bleeding is not controlled, the physician should be contacted.

185

186 Hemophilia A

Laboratory tests for assessing patient status include levels of Factor VIII coagulant, Factor VIII
 antigen and Factor VIII ristocetin cofactor (von Willebrand factor) as well as activated partial
 thromboplastin time. Factor VIII coagulant activity should be determined before giving Stimate[®]
 Nasal Spray for hemostasis. If Factor VIII coagulant activity is present at less than 5% of
 normal, Stimate[®] Nasal Spray should not be relied on.

192

193 von Willebrand's Disease

Laboratory tests for assessing patient status include levels of Factor VIII coagulant activity,VWF:RCo and VWF:Ag.

196

197 **Drug Interactions**

Although the pressor activity of desmopressin acetate is very low, its use with other pressor agents should be done only with careful patient monitoring. The concomitant administration of drugs that may increase the risk of water intoxication with hyponatremia (e.g., tricyclic antidepressants, selective serotonin re-uptake inhibitors, chlorpromazine, opiate analgesics, NSAIDS, lamotrigine and carbamazepine) should be performed with caution.

203

204 DDAVP[®] Injection has been used with epsilon aminocaproic acid without adverse effects.

205

206 Carcinogenicity, Mutagenicity, Impairment of Fertility

- There have been no long-term studies in animals to assess the carcinogenic, mutagenic or impairment of fertility potential of **Stimate**[®] **Nasal Spray**.
- 209

CSL Behring LLC	Stimate [®]	Package Insert
	(desmopressin acetate)	Revised: June 2013
		Page 6

210 Pregnancy Category B

Reproduction studies performed in rats and rabbits by the subcutaneous route at doses up to 10 mcg/kg/day have revealed no evidence of harm to the fetus due to desmopressin acetate. This dose is equivalent to 10 times (for Factor VIII stimulation) or 38 times (for diabetes insipidus) the systemic human dose based on a mg/M² surface area.

215

216 There are no adequate and well-controlled studies in pregnant women. Several publications of desmopressin acetate's use in the management of diabetes insipidus during pregnancy are 217 available; these include a few anecdotal reports of congenital anomalies and low birth weight 218 babies. However, no causal connection between these events and desmopressin acetate has been 219 established. A 15-year, Swedish epidemiologic study of the use of desmopressin acetate in 220 pregnant women with diabetes insipidus found the rate of birth defects to be no greater than that 221 in the general population. As opposed to preparations containing natural hormones, 222 desmopressin acetate in antidiuretic doses has no uterotonic action and the physician will have to 223 224 weigh the therapeutic advantages against the possible risks in each case.

225

226 Nursing Mothers

There have been no controlled studies in nursing mothers. A single study in postpartum women demonstrated a marked change in plasma, but little if any change in assayable DDAVP[®] in breast milk following an intranasal dose of 10 mcg. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when **Stimate[®] Nasal Spray** is administered to a nursing woman.

232

233 Pediatric Use

Use in infants and children will require careful fluid intake restriction to prevent possible hyponatremia and water intoxication. **Stimate**[®] **Nasal Spray** should not be used in infants younger than 11 months in the treatment of hemophilia A or von Willebrand's disease; safety and effectiveness in children between 11 months and 12 years of age has been demonstrated.

239 Geriatric Use

Clinical studies of Stimate[®] did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects. However, other postmarketing experience has indicated the occurrence of hyponatremia with the use of desmopressin acetate and fluid overload.

244

238

Therefore, in elderly patients fluid intake should be adjusted downward in an effort to decrease the potential occurrence of water intoxication and hyponatremia. Particular attention should be paid to the possibility of the rare occurrence of an extreme decrease in plasma osmolality that may result in seizures, and that could lead to coma.

249

Patients who do not have need of antidiuretic hormone for its antidiuretic effect should be cautioned to ingest only enough fluid to satisfy thirst, in an effort to decrease the potential occurrence of water intoxication and hyponatremia.

- 253
- As for all patients, dosing for geriatric patients should be appropriate to their clinical condition.

CSL Behring LLC	Stimate [®]	Package Insert
-	(desmopressin acetate)	Revised: June 2013
		Page 7

255

256 ADVERSE REACTIONS

Infrequently, DDAVP[®] Injection has produced transient headache, nausea, mild abdominal cramps and vulval pain. These symptoms disappeared with reduction in dosage. Occasional facial flushing has been reported with the administration of DDAVP[®] Injection. Infrequently, high doses of intranasal DDAVP[®] have produced transient headache and nausea. Nasal congestion, rhinitis and flushing have also been reported occasionally along with mild abdominal cramps. These symptoms disappeared with reduction in dosage. Nosebleed, sore throat, cough and upper respiratory infections have also been reported.

264

In addition to those listed above, the following have also been reported in clinical trials with Stimate[®] Nasal Spray: Somnolence, dizziness, itchy or light-sensitive eyes, insomnia, chills, warm feeling, pain, chest pain, palpitations, tachycardia, dyspepsia, edema, vomiting, agitation and balanitis.

269

DDAVP[®] Injection (desmopressin acetate) has infrequently produced changes in blood pressure
causing either a slight elevation or a transient fall with a compensatory increase in heart rate.
Severe allergic reactions including anaphylaxis have been reported rarely with DDAVP[®]
Injection.

274

275 **Post Marketing**

There have been rare reports of convulsions from hyponatremia associated with concomitant use of desmopressin and the following medications: oxybutynin and imipramine.

279 See *WARNINGS* for the possibility of water intoxication, hyponatremia and coma.

280

284

278

contact 281 To report SUSPECTED ADVERSE **REACTIONS**, CSL **Behring** 282 **Pharmacovigilance** 1-866-915-6958 FDA 1-800-FDA-1088 at or at or www.fda.gov/medwatch. 283

285 **OVERDOSAGE**

Signs of overdose may include confusion, drowsiness, continuing headache, problems with passing urine and rapid weight gain due to fluid retention. (See *WARNINGS*.) In cases of overdosage, the dosage should be reduced, frequency of administration decreased, or the drug withdrawn according to the severity of the condition.

- 290
- 291 There is no known specific antidote for desmopressin acetate or **Stimate[®] Nasal Spray**.
- 292
- An oral LD_{50} has not been established. An intravenous dose of 2 mg/kg in mice demonstrated no effect.
- 295

296 DOSAGE AND ADMINISTRATION

297 Hemophilia A and von Willebrand's Disease (Type I)

298 **Stimate[®] Nasal Spray** is administered by nasal insufflation, one spray per nostril, to provide a 299 total dose of 300 mcg. In patients weighing less than 50 kg, 150 mcg administered as a single

CSL Behring LLC	Stimate [®]	Package Insert
	(desmopressin acetate)	Revised: June 2013
		Page 8

³⁰⁰ spray provided the expected effect on Factor VIII coagulant activity, Factor VIII ristocetin 301 cofactor activity and skin bleeding time. If **Stimate[®] Nasal Spray** is used preoperatively, it 302 should be administered 2 hours prior to the scheduled procedure.

303

The necessity for repeat administration of **Stimate**[®] **Nasal Spray** or use of any blood products for hemostasis should be determined by laboratory response as well as the clinical condition of the patient. Fluid restriction should be observed, and fluid intake should be limited to a minimum, from 1 hour before desmopressin administration, until at least 24 hours after administration. The tendency toward tachyphylaxis (lessening of response) with repeated administration given more frequently than once every 48 hours should be considered in treating each patient.

- The nasal spray pump can only deliver doses of 0.1 mL (150 mcg) or multiples of 0.1 mL. If doses other than these are required, DDAVP[®] Injection may be used.
- 314

311

- The spray pump must be primed prior to the first use. To prime pump, press down 4 times. The bottle should be discarded after 25 sprays since the amount delivered thereafter per spray may be substantially less than 150 mcg of drug.
- 318

319 HOW SUPPLIED

A 2.5 mL bottle with spray pump capable of delivering 25 sprays of 150 mcg (NDC 0053-6871-00).

322

Store at room temperature not to exceed 25°C (77°F) for the period indicated by the expiration date on the label. Discard six months after being opened. Store bottle in upright position.

IN-8155-09

325

Revised June 2013

- 327
- 328 Manufactured for:
- 329 CSL Behring LLC
- 330 King of Prussia, PA 19406-0901
- 331 US License No. 1767
- 332
- 333 By:
- 334 Ferring GmbH
- 335 Kiel, Germany
- 336 337

	Stimate [®] (desmopressin acetate)	Package Insert Revised: June 2013 Page 9
PATIENT INSTRUCT	TION GUIDE	
	Stimate [®] Nasal S	
	(Pronounced Stin	·
	(desmopressin acc	etate)
Paad this nationt inform	ation leaflet before you start tal	king Stimate[®] Nasal Spray and each tim
		is information does not take the place of
	re provider about your medical	1
		·
What is the most impo	rtant information I should kn	ow about Stimate [®] Nasal Spray?
	@	
All patients using Stir		x for water intoxication, fluid overloa
	$1 \cdot 41 + 11 + 1 = 37$	
instructions on limitin		
instructions on limitin Spray.	ng the amount of fluid you o	an drink when taking Stimate [®] Nasa
instructions on limitinSpray.Do not drink module	ng the amount of fluid you of re than you need to satisfy your	can drink when taking Stimate [®] Nasa
instructions on limitinSpray.Do not drink module	ng the amount of fluid you of re than you need to satisfy your	can drink when taking Stimate [®] Nasa
 instructions on limitin Spray. Do not drink mo You can have s much fluid. Children and elopedation 	ng the amount of fluid you of re than you need to satisfy your erious side effects such as seiz lerly patients are at higher risk	can drink when taking Stimate [®] Nasa thirst. Sures, coma, and death from drinking to for these conditions and <u>must</u> follow the
 instructions on limitin Spray. Do not drink mo You can have s much fluid. Children and elopedation 	ng the amount of fluid you of re than you need to satisfy your erious side effects such as seiz	can drink when taking Stimate[®] Nasa thirst. sures, coma, and death from drinking to for these conditions and <u>must</u> follow the
 instructions on limitin Spray. Do not drink mo You can have s much fluid. Children and elc healthcare provi 	ng the amount of fluid you of re than you need to satisfy your erious side effects such as seiz lerly patients are at higher risk der's restrictions on drinking flu	can drink when taking Stimate [®] Nasa thirst. cures, coma, and death from drinking to for these conditions and <u>must</u> follow the hids.
 instructions on limitin Spray. Do not drink mo You can have s much fluid. Children and elo healthcare provi 	ng the amount of fluid you of re than you need to satisfy your erious side effects such as seiz lerly patients are at higher risk der's restrictions on drinking flu	can drink when taking Stimate [®] Nasa thirst. sures, coma, and death from drinking to for these conditions and <u>must</u> follow the hids.
 instructions on limitin Spray. Do not drink mo You can have s much fluid. Children and elo healthcare provi 	ng the amount of fluid you of re than you need to satisfy your erious side effects such as seiz lerly patients are at higher risk der's restrictions on drinking flu	can drink when taking Stimate [®] Nasa thirst. sures, coma, and death from drinking to for these conditions and <u>must</u> follow the hids.
 instructions on limitin Spray. Do not drink mo You can have s much fluid. Children and elo healthcare provi 	ng the amount of fluid you of re than you need to satisfy your erious side effects such as seiz lerly patients are at higher risk der's restrictions on drinking flu	cures, coma, and death from drinking to for these conditions and <u>must</u> follow the hids.
 instructions on limitin Spray. Do not drink mo You can have s much fluid. Children and elc healthcare provi Call your healthcare pro Stimate[®] Nasal Spray. 	ng the amount of fluid you of re than you need to satisfy your erious side effects such as seiz lerly patients are at higher risk der's restrictions on drinking flu	can drink when taking Stimate [®] Nasa thirst. cures, coma, and death from drinking to for these conditions and <u>must</u> follow the hids. ny of the following symptoms while usin sodium level is low:
 instructions on limitin Spray. Do not drink mo You can have s much fluid. Children and elc healthcare provi Call your healthcare pro Stimate[®] Nasal Spray. Headache 	ng the amount of fluid you of re than you need to satisfy your erious side effects such as seiz lerly patients are at higher risk der's restrictions on drinking flu ovider right away if you have ar They may mean that your blood	can drink when taking Stimate [®] Nasa thirst. cures, coma, and death from drinking to for these conditions and <u>must</u> follow the hids. ny of the following symptoms while usin sodium level is low: Loss of appetite
 instructions on limitin Spray. Do not drink mo You can have s much fluid. Children and elc healthcare provi Call your healthcare provi Stimate[®] Nasal Spray. Headache Nausea 	ng the amount of fluid you of re than you need to satisfy your erious side effects such as seiz lerly patients are at higher risk der's restrictions on drinking flu ovider right away if you have ar They may mean that your blood	can drink when taking Stimate[®] Nasa thirst. cures, coma, and death from drinking to for these conditions and <u>must</u> follow the hids. by of the following symptoms while usin sodium level is low: Loss of appetite Irritability
 instructions on limitin Spray. Do not drink mo You can have s much fluid. Children and elc healthcare provi Call your healthcare provi Call your healthcare provi Headache Nausea Vomiting 	ng the amount of fluid you of the rest of the r	can drink when taking Stimate [®] Nasa thirst. cures, coma, and death from drinking to for these conditions and <u>must</u> follow the hids. by of the following symptoms while usin sodium level is low: Loss of appetite Irritability Muscle weakness

375

CSL Behring LLC	Stimate [®]	Package Insert
	(desmopressin acetate)	Revised: June 2013
		Page 10

376 377	What should I tell my healthcare provider before I use Stimate [®] Nasal Spray?
378 379	Before taking Stimate [®] Nasal Spray, tell your healthcare provider about all of your medical conditions, including if you:
380 381 382	• Have any nasal problems such as a stuffy nose, have ever had surgery on your nose, or have trouble breathing through your nose. You may need to use another form of this medicine.
383 384 385	 Have or have had any heart, blood circulation, or blood pressure problems. Have a condition that causes fluid or water imbalance problems such as: Cystic fibrosis
386 387	Heart failureKidney problems
388 389 390	 Have or have had a condition that causes you to be very thirsty. Are pregnant or plan to become pregnant. It is not known if Stimate[®] Nasal Spray will harm your unborn baby.
 391 392 393 394 	• Are breast-feeding or plan to breast-feed. It is not known if Stimate [®] Nasal Spray passes into your breast milk. You and your healthcare provider should decide if you will take Stimate [®] Nasal Spray.
395 396 397 398	Tell your healthcare provider and pharmacist about all the medicines you take, including prescription and non-prescription medicines, such as over-the-counter medicines, vitamins, supplements and herbal remedies.
399 399 400 401	Using Stimate [®] Nasal Spray with certain other medicines can affect the way Stimate [®] Nasal Spray works.
402 403 404	Know the medicines you take. Keep a list of them and show it to your healthcare provider and pharmacist when you get a new medicine.
405 406	 It is especially important to tell your healthcare provider if you take: Blood pressure or heart medicines
407 408	 Antidepressants Anti-anxiety medicines Antihistamines
409 410 411	 Antifistammes Pain relievers such as narcotics or non-steroidal anti-inflammatory medicines (NSAIDs) Seizure medicines
412 413	 Medicines for over-active urinary bladder
414 415	Ask your healthcare provider or pharmacist if you are not sure if your medicine is one of these.
416 417 418	 How should I use Stimate[®] Nasal Spray? Use Stimate[®] Nasal Spray exactly as your healthcare provider told you. Do not use more Stimate[®] Nasal Spray or take it more often than your healthcare provider told you.

CSL Behring LLC	Stimate [®]	Package Insert
-	(desmopressin acetate)	Revised: June 2013
		Page 11

419 420	• The Stimate [®] Nasal Spray pump provides the correct dose of your medicine. For detailed instructions on how to use the nasal spray pump, see the <i>Patient Instructions for Use</i> at
421	the end of this leaflet.
422	• The nasal spray pump delivers 25 sprays of Stimate [®] Nasal Spray and each spray
423	contains a measured amount of medicine. Any medicine left in the spray pump after 25
424	sprays should be thrown away because, at that time, the amount of medicine in each
425	spray may be a lot less than the correct amount. Do not put any leftover medicine into
426	another bottle.
427	• If your symptoms do not improve, or if they become worse, contact your healthcare
428	provider. Do not stop taking Stimate [®] Nasal Spray without talking to your healthcare
429	provider.
430	• If you use too much Stimate [®] Nasal Spray, call your healthcare provider or go to the
431 432	nearest hospital emergency department right away.
433	What are the possible side effects of Stimate [®] Nasal Spray?
434	
435 436	Stimate [®] Nasal Spray may cause serious side effects that come from having too much water in the body. See "What is the most important information I should know about Stimate [®] Nasal
437	Spray?".
438	
439	Common side effects of Stimate Nasal Spray include:
440	Occasional facial flushing
441	• Nasal congestion
442	Runny nose
443	 Nosebleed
444	
445	• Cough
446 447	• Upper respiratory infections.
448	Tell your healthcare provider about any side effect that bothers you or does not go away. These
449	are not all the possible side effects of Stimate [®] Nasal Spray. If you have questions, talk to your
450	healthcare provider.
451	neutrieure provider.
452	Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-
453	800-FDA-1088.
455 454	000-1 DA-1000.
	How should I store Stimate [®] Nasal Spray?
455	
456	• Store at room temperature, but not higher than $77^{\circ}F(25^{\circ}C)$.
457	• Throw away Stimate [®] Nasal Spray six months after it is opened, or when the expiration
458	date has passed, if this date is before the six months is up.
459	• Store Stimate [®] Nasal Spray standing upright.
460	
461	Keep Stimate [®] Nasal Spray and all medicines out of the reach of children.
462	
463	
	GRDC\Cabinets\RA Labeling\Stimate\USA\Package Insert, Blank [778759] \Rev. 11/2012_ CBE_Delete References VERSION 17.0

CSL Behring LLC	Stimate®	Package Insert
	(desmopressin acetate)	Revised: June 2013
		Page 12

464 General information about Stimate[®] Nasal Spray

Medicines are sometimes prescribed for conditions that are not mentioned in the patient leaflet.
Do not use Stimate[®] Nasal Spray for a condition for which it was not prescribed. Do not give
Stimate[®] Nasal Spray to other people, even if they have the same symptoms you have. It may
harm them.

469

This patient information leaflet summarizes the most important information about Stimate[®]
Nasal Spray. If you would like more information about Stimate[®] Nasal Spray, talk with your
healthcare provider. You can ask your healthcare provider or pharmacist for information about
Stimate[®] Nasal Spray that is written for health professionals. For more information, go to *www.stimate.com* or call CSL Behring Medical Affairs at 1-800-504-5434.

476 What are the ingredients in Stimate[®] Nasal Spray?

- 478 Active ingredients: desmopressin acetate
- 479 Inactive ingredients: sodium chloride, citric acid monohydrate, disodium phosphate dihydrate,
 480 benzalkonium chloride, purified water.
- 481 482

475

477

483 **Patient Instructions for Use**

484

Read these instructions carefully before you use your Stimate[®] Nasal Spray pump. The
following instructions tell you how to prepare, or prime, your Stimate[®] Nasal Spray pump so that
it is ready to use.


489 Using your Stimate[®] Nasal Spray Pump

490 491

492

488

- **1.** Remove the protective cap.
- When using Stimate[®] Nasal Spray for the first time, the spray pump must be primed by pressing down on the ring at the top of the pump 4 times. Hold the spray tip away from your face and eyes. See Figure A.
- 496



497

498 Figure A

CSL Behring LLC	Stimate [®]	Package Insert
-	(desmopressin acetate)	Revised: June 2013
		Page 13

499
500

505

3. When primed, the Stimate[®] Nasal Spray pump delivers one dose of medicine each time it is pressed. For the right dose, tilt your Stimate[®] Nasal Spray pump so that the tube inside the spray pump draws the medicine up from the deepest part of the medicine inside the container. See Figures A and B.



506		
507	Figure	B
508 509 510 511	4.	Put the spray nozzle tip into your nostril and press the spray pump one time for one dose (150-micrograms). If two doses are prescribed, spray each nostril one time (for a dose of 300-micrograms).
512 513 514	5.	When you finish using your Stimate [®] Nasal Spray, put the cap over the tip of the pump.
515 516 517 518	6.	If Stimate [®] Nasal Spray has not been used for one week, you will need to prime the pump again by pressing one time, or until you see a fine mist.

CSL Behring LLC	Stimate [®]	Package Insert
_	(desmopressin acetate)	Revised: June 2013
		Page 14

519 Use this check-off chart to help you keep track of the number of sprays used. This will help 520 make sure that you receive 25 sprays with each bottle of Stimate[®] Nasal Spray. There is extra 521 medicine in the bottle to allow for priming. When using the chart to check off sprays, do not 522 count the priming sprays.

523

- 524
- 525

526

Stimate [®] Nasal Spray		
25 Spray Check-off Chart		

1	2	3	4	5
6	I	(8)	9	10
11	12	13	14	15
16	$\overline{0}$	18	19	20
21	22	23	24	25

527

Keep this chart with your Stimate[®] Nasal Spray or put it someplace where you can easily get it.

530

Check off number 1 on the chart with your first dose of Stimate[®] Nasal Spray. Check off the numbers after each use of Stimate[®] Nasal Spray. If your healthcare provider prescribed a 2-spray dose (300-micrograms), then two numbers should be checked off.

534

535 **3.** Throw away the Stimate[®] Nasal Spray after 25 sprays.

536 537

IN-8155-09